IMMU-24. A COMPREHENSIVE IN SILICO APPROACH TO DISCOVERING TUMOR REJECTION ANTIGENS IN MALIGNANT BRAIN TUMORS
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz175.517
Abstract: Proteins that can serve as effective tumor rejection antigens within brain tumors are poorly characterized. Current prediction algorithms relying on identification of mutated epitopes as neoantigens are limited in low mutational burden tumors. We have… read more here.
Keywords: rejection antigens; brain tumors; tumor rejection; tumor ... See more keywords
721 AT1412, a patient-derived CD9 antibody in preclinical development promoting tumor immune infiltration and inducing tumor rejection
Sign Up to like & getrecommendations! Published in 2020 at "Journal for ImmunoTherapy of Cancer"
DOI: 10.1136/jitc-2020-sitc2020.0721
Abstract: Background Adaptive immunity to cancer cells forms a crucial part of cancer immunotherapy. Recently, the importance of tumor B-cell signatures were shown to correlate with melanoma survival. We investigated whether tumor-targeting antibodies could be isolated… read more here.
Keywords: melanoma; preclinical development; infiltration; rejection ... See more keywords
Abstract 4497: Delineating the effects of different levels of nitric oxide produced by "M1" stimulated macrophages on tumor rejection and response to therapy
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-4497
Abstract: Nitric Oxide (NO) was historically known to be immunosuppressive in cancers by inhibiting T-cell function and endothelial activation. This is relevant however only in the aberrant, dysfunctional tumor vasculature. Recently, local low dose irradiation was… read more here.
Keywords: different levels; stimulated macrophages; tumor rejection; nitric oxide ... See more keywords
cDC1 vaccines drive tumor rejection by direct presentation independently of host cDC1.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer immunology research"
DOI: 10.1158/2326-6066.cir-21-0865
Abstract: As a cell-based cancer vaccine, dendritic cells (DCs), derived from peripheral blood monocytes or bone marrow (BM) treated with GM-CSF (GMDCs), were initially thought to induce antitumor immunity by presenting tumor antigens directly to host… read more here.
Keywords: anti tumor; cdc1; host cdc1; tumor ... See more keywords